For decades, deglycyrrhizinated licorice, known as DGL, has been utilized in clinical settings, primarily for addressing peptic ulcers. Licorice contains numerous triterpenoids and hundreds of flavonoids that demonstrate inhibitory effects on various inflammatory enzymes, including cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX). These enzymes play a role in reducing the production of potent inflammatory compounds like IL-6, prostaglandin E2, thromboxane B2, and leukotriene B4. Notably, the removal of glycyrrhizic acid, a component associated with mineralocorticoid excess and hypertension, in DGL highlights its anti-inflammatory potential. Licorice comprises multiple active compounds, including glabridin and at least seven licochalcones, which exhibit anti-inflammatory, antimicrobial, and anti-allergic actions. Research indicates their ability to prevent lipopolysaccharide (LPS)-induced production of inflammatory compounds, inhibit yeast and bacterial biofilm formation, and enhance the activity of antioxidant enzymes.

In clinical studies, DGL has demonstrated efficacy comparable to cimetidine for both ulcer healing and the Preventive-Wellness-Car-e of ulcer recurrences. Moreover, licorice extracts have shown inhibitory effects on H. pylori adhesion to gastric mucosa and the Development of antibiotic-resistant strains, suggesting multiple mechanisms for its anti-ulcer benefits. The use of chewable tablets is deemed necessary for the efficacy of DGL, facilitating distribution and absorption by the gastric mucosa.

Benefits

• Provides DGL in chewable tablets, the form associated with the greatest clinical efficacy, as it allows for licorice to be released in the stomach and dispersed/absorbed by the gastric mucosa
• Offers 400 mg of DGL per tablet, the clinically effective dosage
• Deglycyrrhizination prevents adverse effects associated with licorice consumption
• Pleasant-tasting tablets for better compliance